Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
STRATEGY
Novartis maintains strong commitment to shareholder value creation
Investing in the business
Investments in organic business
R&D >USD 45bn, CAPEX >USD 5bn 2018-YTD 20231
Value-creating bolt-ons
>USD 33bn 2018-YTD 2023
Substantial
cash
generation
Whilst also creating shareholder value via numerous strategic actions
Jun 2018
Divested consumer
health JV
1. Core R&D and CAPEX actuals. 2. In CHF.
27 Investor Relations | Q3 2023 Results
Apr 2019
Spun Alcon
Returning capital to shareholders
Consistently growing annual dividend²
>USD 42bn of dividends 2018-YTD 2023
No rebasing post Alcon and Sandoz spin-off
Share buybacks
>USD 30bn 2018-YTD 2023
New USD 15bn SBB commenced in Jul 2023
Nov 2021
Oct 2023
Exited Roche stake
Spun Sandoz
NOVARTIS | Reimagining MedicineView entire presentation